​

Funding Round

Series C - Edgewise Therapeutics

Series C - Edgewise Therapeutics

Investment Firm

Overview

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.

Announced Date

Dec 08, 2020

Funding Type

Series C

Highlights

Location

United States, North America

Social

Investor Lead

Viking Global Investors

Viking Global Investors

Viking Global Investors is a early_stage_venture and late_stage_venture firm.

Participant Investors

12

Investor Name
Participant InvestorNovo Holdings
Participant InvestorDeerfield
Participant InvestorCitadel
Participant InvestorWellington Management
Participant InvestorU.S. Venture Partners

Round Details and Background

Edgewise Therapeutics raised $95000000 on 2020-12-08 in Series C

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.

Company Funding History

5

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Aug 01, 2018
Series A - Edgewise Therapeutics
-15.5M
Dec 08, 2020
Series C - Edgewise Therapeutics
14-95.0M
Sep 13, 2022
Post-IPO Equity - Edgewise Therapeutics
-138.0M
Jan 19, 2024
Post-IPO Equity - Edgewise Therapeutics
-240.0M

Recent Activity

There is no recent news or activity for this profile.